EGFR and glioblastoma: Analysis on molecular glioblastoma subtypes (mesenchymal, RTK I, RTK II) showed that all three molecular subtypes were evenly distributed in the analyzed cohort (Supplementary Figure S1a); however, there was a predominance of RTK II subtype in EGFR amplified glioblastomas (60%, Supplementary Figure S1b) and a predominance of RTK I subtype in EGFR non-amplified glioblastomas (48%, Supplementary Figure S1c).